Epidermal Growth Factor Reduction (EFGR) Articles

Articles

  • TAT-10: Bi-213-anti-EGFR-Mab Therapy of Recurrent Bladder Cancer - A Pilot Study

    Kanazawa, Japan (UroToday.com) Patients with non-muscle invasive bladder cancer treated with surgical resection and chemotherapy with Bacillus Calmette-Guerin (BCG) experience up to 40% relapse and require bladder removal. Following successful treatment using Bi-213 labeled Epidermal Growth Factor Reduction (EFGR) Mab in mice, a pilot study was undertaken with 12 human patients (10 male, 2 female).
    Published June 21, 2017